BR112013013950A2 - antagonista de lpa1 policíclico e usos dos mesmos - Google Patents

antagonista de lpa1 policíclico e usos dos mesmos

Info

Publication number
BR112013013950A2
BR112013013950A2 BR112013013950A BR112013013950A BR112013013950A2 BR 112013013950 A2 BR112013013950 A2 BR 112013013950A2 BR 112013013950 A BR112013013950 A BR 112013013950A BR 112013013950 A BR112013013950 A BR 112013013950A BR 112013013950 A2 BR112013013950 A2 BR 112013013950A2
Authority
BR
Brazil
Prior art keywords
lpa1 antagonist
polycyclic
pharmaceutically acceptable
lpa1
antagonist
Prior art date
Application number
BR112013013950A
Other languages
English (en)
Inventor
Christophier David King
Jason Edward Brittain
Thomas Jon Seiders
Victor W Rosso
Original Assignee
Amira Pharmaceuticals Inc
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amira Pharmaceuticals Inc, Bristol Myers Squibb Co filed Critical Amira Pharmaceuticals Inc
Publication of BR112013013950A2 publication Critical patent/BR112013013950A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)

Abstract

antagonista de lpa1 policíclico e usos dos mesmos é descrito aqui o antagonista de lpa1 ácido 1-{4'-[3-metil-4-(r)-1-fenil-etoxicarbonilamino)-isoxazol-5-il]-bifenil-4-il}-ciclopropanocarboxílico (composto 1), ou sais farmaceuticamente aceitáveis do mesmo. são também descritos métodos de preparação do antagonista de lpa1, ou sais farmaceuticamente aceitáveis do mesmo, bem como composições farmacêuticas adequadas para administração a um mamíferoque inclui o antagonista de lpa1, ou sal farmaceuticamente aceitável do mesmo, e métodos de uso de tais composições farmacêuticas para tratar doenças ou condições dependentes de lpa ou mediadas por lpa.
BR112013013950A 2010-12-07 2011-12-07 antagonista de lpa1 policíclico e usos dos mesmos BR112013013950A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42059910P 2010-12-07 2010-12-07
PCT/US2011/063817 WO2012078805A1 (en) 2010-12-07 2011-12-07 Polycyclic lpa1 antagonist and uses thereof

Publications (1)

Publication Number Publication Date
BR112013013950A2 true BR112013013950A2 (pt) 2016-09-27

Family

ID=45446189

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013013950A BR112013013950A2 (pt) 2010-12-07 2011-12-07 antagonista de lpa1 policíclico e usos dos mesmos

Country Status (25)

Country Link
US (2) US9556133B2 (pt)
EP (2) EP2648726B1 (pt)
JP (1) JP6030567B2 (pt)
KR (1) KR101875246B1 (pt)
CN (2) CN107721940A (pt)
AU (2) AU2011338417B2 (pt)
BR (1) BR112013013950A2 (pt)
CA (1) CA2820884A1 (pt)
CY (1) CY1120342T1 (pt)
DK (1) DK2648726T3 (pt)
EA (1) EA024967B1 (pt)
ES (1) ES2674174T3 (pt)
HR (1) HRP20180970T1 (pt)
HU (1) HUE040397T2 (pt)
IL (1) IL226698B (pt)
LT (1) LT2648726T (pt)
MX (1) MX347544B (pt)
NO (1) NO2648726T3 (pt)
PL (1) PL2648726T3 (pt)
PT (1) PT2648726T (pt)
RS (1) RS57377B1 (pt)
SG (1) SG191041A1 (pt)
SI (1) SI2648726T1 (pt)
TR (1) TR201809293T4 (pt)
WO (1) WO2012078805A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011338561A1 (en) 2010-12-07 2013-07-25 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and their use in the treatment of fibrosis
US8975235B2 (en) 2011-03-20 2015-03-10 Intermune, Inc. Lysophosphatidic acid receptor antagonists
MX369801B (es) 2012-12-28 2019-11-21 Ube Industries Compuesto heterociclico sustituido con halogeno.
TW201437200A (zh) * 2013-01-15 2014-10-01 Intermune Inc 溶血磷脂酸受體拮抗劑
SG11201507459YA (en) 2013-03-15 2015-10-29 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
SG11201510011VA (en) 2013-06-07 2016-01-28 California Inst Biomedical Res Small molecule inhibitors of fibrosis
WO2015066456A1 (en) 2013-10-31 2015-05-07 Bristol-Myers Squibb Company Radioligands for imaging the lpa-1 receptor
CN105848718B (zh) * 2013-12-04 2019-07-30 盖尔梅德研究与发展有限公司 Aramchol盐
GB201410741D0 (en) * 2014-06-17 2014-07-30 Babraham Inst And University Of Birmingham The Novel diagnostic and therapeutic method
CA2953472C (en) 2014-06-27 2022-08-02 Ube Industries, Ltd. Halogen-substituted heterocyclic compound salt
EP3302465A1 (en) 2015-06-05 2018-04-11 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
JPWO2017086430A1 (ja) * 2015-11-20 2018-09-06 宇部興産株式会社 Ｎａｓｈの治療又は予防のための医薬組成物
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
CN108318447B (zh) * 2018-05-04 2020-12-18 山东大学 一种基于近红外光谱技术快速测定吡喹酮对映体组成的方法
TW202016090A (zh) 2018-06-07 2020-05-01 瑞士商愛杜西亞製藥有限公司 經烷氧基取代之吡啶基衍生物
KR102224677B1 (ko) * 2018-08-23 2021-03-08 가천대학교 산학협력단 티아졸로 피페라진 유도체 및 이를 유효성분으로 함유하는 자가면역질환 예방 또는 치료용 조성물
EP3853232B1 (en) * 2018-09-18 2023-03-01 Bristol-Myers Squibb Company Oxabicyclo acids as lpa antagonists
AR119162A1 (es) 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd Derivados de piridin-3-ilo
CA3158743A1 (en) 2019-11-15 2021-05-20 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
KR20220109439A (ko) 2019-12-04 2022-08-04 이도르시아 파마슈티컬스 리미티드 섬유증 질환의 치료에서 사용하기 위한 아제티딘 lpa1 수용체 길항제와 피르페니돈 및/또는 닌테다닙의 조합
KR102393079B1 (ko) 2020-02-28 2022-04-29 한국화학연구원 가축 호흡기 질환의 예방 또는 치료용 조성물
CN111608208B (zh) * 2020-05-19 2022-01-11 浙江鲁班建材科技股份有限公司 一种时间可控制的吸水膨胀堵漏型预铺卷材
IL298082A (en) 2020-06-03 2023-01-01 Gilead Sciences Inc lpa receptor antagonists and uses thereof
WO2021247215A1 (en) 2020-06-03 2021-12-09 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
WO2022240879A1 (en) 2021-05-11 2022-11-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
WO2023107938A1 (en) 2021-12-08 2023-06-15 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
KR102463504B1 (ko) 2022-08-23 2022-11-04 주식회사 에네스지 원전 습분분리재열기의 종단온도차 보정 방법

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
AU2001232340A1 (en) * 2000-02-18 2001-08-27 Kirin Beer Kabushiki Kaisha Novel isoxazole and thiazole compounds and use thereof as drugs
US20030215462A1 (en) 2001-12-21 2003-11-20 Wacher Vincent J. Use of UGT inhibitors to increase bioavailability
US20040014648A1 (en) 2002-05-17 2004-01-22 Faust Pharmaceuticals Methods for the prevention and/or the treatment of neurological disorders
US7060697B2 (en) 2003-05-19 2006-06-13 Irm Llc Immunosuppressant compounds and compositions
WO2007016784A1 (en) 2005-08-11 2007-02-15 Merck Frosst Canada Ltd. Novel substituted 1,2,3-tπazolylmethyl-benzothiophene or -indole and their use as leukotπene biosynthesis inhibitors
AR055041A1 (es) 2005-03-23 2007-08-01 Merck Frosst Canada Ltd Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.
US7405302B2 (en) 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
US20070225285A1 (en) 2005-11-04 2007-09-27 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US20070219206A1 (en) 2005-11-04 2007-09-20 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
CA2636043A1 (en) 2006-01-23 2007-08-02 Amira Pharmaceuticals, Inc. Tricyclic inhibitors of 5-lipoxygenase
GB2466121B (en) 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors

Also Published As

Publication number Publication date
US9556133B2 (en) 2017-01-31
AU2016238848A1 (en) 2016-10-27
MX347544B (es) 2017-05-02
HRP20180970T1 (hr) 2018-08-10
EP2648726B1 (en) 2018-04-04
PT2648726T (pt) 2018-06-25
US20130253023A1 (en) 2013-09-26
RS57377B1 (sr) 2018-08-31
CN103596566A (zh) 2014-02-19
ES2674174T3 (es) 2018-06-27
EP2648726A1 (en) 2013-10-16
AU2016238848B2 (en) 2018-03-29
WO2012078805A1 (en) 2012-06-14
SI2648726T1 (en) 2018-06-29
EA024967B1 (ru) 2016-11-30
EA201390840A1 (ru) 2013-10-30
MX2013006394A (es) 2013-09-13
HUE040397T2 (hu) 2019-03-28
LT2648726T (lt) 2018-06-25
AU2011338417B2 (en) 2016-12-01
TR201809293T4 (tr) 2018-07-23
JP6030567B2 (ja) 2016-11-24
CY1120342T1 (el) 2019-07-10
SG191041A1 (en) 2013-08-30
US20170121295A1 (en) 2017-05-04
NO2648726T3 (pt) 2018-09-01
DK2648726T3 (da) 2018-07-16
CN107721940A (zh) 2018-02-23
CN103596566B (zh) 2017-08-25
CA2820884A1 (en) 2012-06-14
EP3360552A1 (en) 2018-08-15
PL2648726T3 (pl) 2018-10-31
AU2011338417A1 (en) 2013-07-25
KR20130124524A (ko) 2013-11-14
KR101875246B1 (ko) 2018-07-05
JP2013544890A (ja) 2013-12-19
IL226698B (en) 2018-05-31

Similar Documents

Publication Publication Date Title
BR112013013950A2 (pt) antagonista de lpa1 policíclico e usos dos mesmos
EA201490647A1 (ru) Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции
BR112015020787A2 (pt) inibidores quinazolínicos de formas mutantes ativantes do receptor do fator de crescimento epidérmico
PH12014502041A1 (en) Heterocyclyl compounds as mek inhibitors
BR112015016001A2 (pt) compostos, composições farmacêuticas e respectivos usos e método para tratar ou prevenir infecção bacteriana
WO2011159550A3 (en) Lysophosphatidic acid receptor antagonist and uses thereof
BR112015023412A8 (pt) 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante, sua composição farmacêutica e seu uso.
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
MX2020003055A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
AR090292A1 (es) Compuestos basados en pirazolo[1,5-a]pirimidina, composiciones que los comprenden y metodos que los utilizan
BR112014011850A8 (pt) Derivados de aminopirimidina, seus usos, e composição farmacêutica
BR112012029405A8 (pt) compostos macrocíclicos como inibidores de trk quinase
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112012017310A2 (pt) derivados de triazol substituídos como moduladores de gama secretase
BR112014010105A2 (pt) aminas de c-28 de derivados de ácido betulínico modificado por c-3 como inibidores de maturação de hiv
BR112015001419A8 (pt) composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
BR112014010576A2 (pt) inibidores de neprilisina
EA201500265A1 (ru) Ингибиторы репликации вирусов гриппа
BR112015014458A8 (pt) compostos derivados de manose, seus intermediários, composição, uso e processos de preparação
BR112015019590A2 (pt) derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112014027117A8 (pt) Derivados de pirazol aminopirimidina como moduladores de lrrk2, seus usos, e composição

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.